(PURR) Hyperliquid Strategies - Overview

Sector: Financial Services | Industry: Capital Markets | Exchange: NASDAQ (USA) | Market Cap: 698m USD | Total Return: 66.7% in 12m

Biologic Medicines, Single Action, Bifunctional Platform

Total Rating 43

Safety 87

Buy Signal 1.26

Capital Markets
Industry Rotation: +18.3

Market Cap: 698M
Avg Turnover: 27.2M USD

ATR: 8.97%
Peers RS (IBD): 70.3

Risk 5d forecast

Volatility105%

Rel. Tail Risk-9.32%

Reward TTM

Sharpe Ratio1.84

Alpha48.59

Character TTM

Beta0.621

Beta Downside-6.066

Drawdowns 3y

Max DD29.35%

CAGR/Max DD11.31

EPS (Earnings per Share)

EPS CAGR: -99.98%
EPS Trend: -100.0%

Qual. Beats: 0

Revenue

Warnings

Share dilution 1950.0% YoY - potential capital distress

Tailwinds

No distinct edge detected

Description: PURR Hyperliquid Strategies

Hyperliquid Strategies Inc. (NASDAQ: PURR) is a U.S.-based biotechnology firm, incorporated in 2025 and headquartered in New York, that develops a platform for single- and bifunctional biologic medicines through its subsidiary.

As of the latest quarter, the biotech sector’s R&D intensity remains high, with industry-wide spending up 7% YoY, and PURR reported a cash runway of roughly 18 months supporting its early-stage pipeline. The company’s lead candidate is in Phase 1 trials targeting an unmet autoimmune indication, a market projected to grow at a 5.4% CAGR through 2030.

For a deeper dive into PURR’s fundamentals and valuation, consider exploring the analysis on ValueRay.

Headlines to Watch Out For

Biotechnology platform advances drive drug development revenue
Regulatory approval delays threaten product pipeline
Research and development costs impact profitability
Competition intensifies in biologic medicines market

What is the price of PURR shares? As of April 14, 2026, the stock is trading at USD 6.50 with a total of 6,744,132 shares traded.
Over the past week, the price has changed by +28.71%, over one month by +22.18%, over three months by +73.33% and over the past year by +66.67%.

Is PURR a buy, sell or hold? Hyperliquid Strategies has no consensus analysts rating.

What are the forecasts/targets for the PURR price?

Analysts Target Price	-	-

Hyperliquid Strategies (PURR) - Fundamental Data Overview as of 11 April 2026

Revenue TTM = 0.0 USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 697.9m USD (697.9m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 697.9m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 697.9m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 8.17% (E(697.9m)/V(697.9m) * Re(8.17%) + (debt-free company))
Discount Rate = 8.17% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -46.55%
[DCF] Fair Price = unknown (Cash Flow 0.0)
EPS Correlation: -100.0 | EPS CAGR: -99.98% | SUE: N/A | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.39 | Chg7d=-0.265 | Chg30d=-0.265 | Revisions Net=+0 | Analysts=2

External Resources

Dataroma Stockcircle